| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258) | National Cancer Institute (NCI) | 2022-07-26 |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (NCT05432193) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2022-07-13 |
| Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer (NCT05936502) | Head and Neck Cancer International Group | 2022-07-11 |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT04831450) | University of Miami | 2022-07-01 |
| Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC (NCT05351762) | Xijing Hospital | 2022-07-01 |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (NCT05286294) | Oslo University Hospital | 2022-06-28 |
| SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome (NCT05400239) | Guy's and St Thomas' NHS Foundation Trust | 2022-06-01 |
| PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS (NCT06413095) | Presage Biosciences | 2022-06-01 |
| BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) (NCT05299203) | West China Hospital | 2022-05-01 |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (NCT05229601) | HiFiBiO Therapeutics | 2022-04-20 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (NCT05363605) | Fusion Pharmaceuticals Inc. | 2022-04-20 |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC (NCT05077709) | IO Biotech | 2022-04-11 |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC (NCT05220748) | Rakuten Medical, Inc. | 2022-03-24 |
| Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck (NCT05291663) | Assiut University | 2022-03-20 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (NCT05238883) | HiFiBiO Therapeutics | 2022-03-10 |
| The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC (NCT05343325) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2022-03-09 |
| Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (NCT05286060) | Yonsei University | 2022-03-01 |
| Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC (NCT05272696) | Guangdong Provincial People's Hospital | 2022-03-01 |
| Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality (NCT05031910) | Thomas Jefferson University | 2022-02-04 |
| RTX-224 Monotherapy in Patients With Solid Tumors (NCT05219578) | Rubius Therapeutics | 2022-01-12 |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) (NCT04938609) | Providence Health & Services | 2022-01-11 |
| Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy (NCT05918224) | West China Hospital | 2022-01-01 |
| Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (NCT05117138) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2022-01-01 |
| A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC (NCT05054439) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-12-22 |
| Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors (NCT05145907) | TJ Biopharma Co., Ltd. | 2021-12-22 |
| Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients (NCT05099952) | Roswell Park Cancer Institute | 2021-12-15 |
| The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors (NCT05821751) | Fondazione del Piemonte per l'Oncologia | 2021-12-02 |
| Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck Carcinoma (NCT05156177) | Institute of Oncology Ljubljana | 2021-12-01 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) (NCT05136768) | Jun-Lin Yi, MD | 2021-12-01 |
| Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC (NCT05047094) | Alpha Tau Medical LTD. | 2021-11-02 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (NCT05005403) | AbbVie | 2021-11-01 |
| A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC (NCT05044897) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-10-20 |
| Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117) | Sun Yat-sen University | 2021-10-18 |
| A Study of NX-1607 in Adults With Advanced Malignancies (NCT05107674) | Nurix Therapeutics, Inc. | 2021-09-29 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (NCT04854499) | Gilead Sciences | 2021-09-07 |
| Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence (NCT05065086) | Royal Marsden NHS Foundation Trust | 2021-09-02 |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers (NCT04946968) | National Cancer Centre, Singapore | 2021-08-24 |
| Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery (NCT05024019) | Eye & ENT Hospital of Fudan University | 2021-08-21 |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (NCT05075122) | Martin-Luther-Universität Halle-Wittenberg | 2021-08-02 |
| PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT (NCT05008796) | Chang Gung Memorial Hospital | 2021-08-01 |
| SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification (NCT04803331) | Radboud University Medical Center | 2021-07-27 |
| PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC (NCT06062602) | Presage Biosciences | 2021-07-26 |
| Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 (NCT04999800) | Shi Yuankai | 2021-07-18 |
| Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients (NCT04752384) | Medical College of Wisconsin | 2021-07-08 |
| Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) (NCT04807140) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-07-08 |
| MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (NCT04651634) | MitoImmune Therapeutics | 2021-06-21 |
| Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma (NCT05143268) | Lorenzo Livi | 2021-06-03 |
| Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT04843098) | Suzhou Junde Biotechnology Co., Ltd | 2021-05-26 |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) (NCT04675333) | ALX Oncology Inc. | 2021-05-10 |
| RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (NCT04762225) | Repertoire Immune Medicines | 2021-05-10 |
| Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China (NCT04857164) | Yuankai Shi | 2021-04-30 |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (NCT04868877) | Merus B.V. | 2021-04-28 |
| JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (NCT04721223) | Jacobio Pharmaceuticals Co., Ltd. | 2021-04-26 |
| Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (NCT04848116) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-04-24 |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (NCT04624113) | Washington University School of Medicine | 2021-04-14 |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) (NCT04675294) | ALX Oncology Inc. | 2021-04-02 |
| Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC (NCT04826679) | Sun Yat-sen University | 2021-04-01 |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer (NCT04634825) | MacroGenics | 2021-03-17 |
| Evaluation of OE-MRI in Patients With H&N Cancer (NCT04724096) | Nottingham University Hospitals NHS Trust | 2021-03-04 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (NCT04681469) | Gruppo Oncologico del Nord-Ovest | 2021-02-08 |
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China (NCT04740996) | Shi Yuankai | 2021-02-04 |
| A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (NCT04722523) | Memorial Sloan Kettering Cancer Center | 2021-01-20 |
| Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma (NCT05476965) | Hubei Cancer Hospital | 2021-01-01 |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (NCT03740256) | Baylor College of Medicine | 2020-12-14 |
| The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs (NCT05202275) | Chinese Academy of Medical Sciences | 2020-12-01 |
| Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer (NCT04452032) | Jules Bordet Institute | 2020-11-17 |
| A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (NCT05523323) | Merck Sharp & Dohme LLC | 2020-10-30 |
| Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (NCT04616196) | Nektar Therapeutics | 2020-10-30 |
| Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (NCT04357873) | UNICANCER | 2020-10-28 |
| Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma (NCT04599309) | University Health Network, Toronto | 2020-10-15 |
| 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC (NCT04196985) | Turku University Hospital | 2020-10-01 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors (NCT04452214) | Cantargia AB | 2020-09-24 |
| Specific Methylation Profiles in HNSCC (NCT04567056) | Aalborg University Hospital | 2020-09-16 |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer (NCT04555837) | M.D. Anderson Cancer Center | 2020-09-15 |
| Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients (NCT04414540) | Trisha Wise-Draper | 2020-08-31 |
| Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NCT04694846) | Thomas Jefferson University | 2020-08-19 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| Sodium Selenite Supplementation in Patients With Head and Neck Cancer (NCT05451576) | Chang Gung Memorial Hospital | 2020-08-12 |
| Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (NCT04523883) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2020-08-10 |
| Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors (NCT04297995) | Shanghai Henlius Biotech | 2020-07-29 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China (NCT04121286) | Allist Pharmaceuticals, Inc. | 2020-07-14 |
| HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma (NCT04369937) | Dan Zandberg | 2020-07-06 |
| Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (NCT04375384) | Wake Forest University Health Sciences | 2020-07-01 |
| A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (NCT07435311) | R-Pharm | 2020-06-15 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (NCT04074967) | Dan Zandberg | 2020-06-11 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542) | Bicara Therapeutics | 2020-06-01 |
| A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer (NCT04193293) | SecuraBio | 2020-06-01 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (NCT04291105) | Vyriad, Inc. | 2020-04-24 |
| Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer (NCT03993353) | University of California, San Diego | 2020-04-07 |
| Ribociclib and Spartalizumab in R/M HNSCC (NCT04213404) | National Taiwan University Hospital | 2020-03-13 |
| Epigenetic Changes in Head and Neck Cancer (NCT04260074) | Aalborg University Hospital | 2020-03-11 |
| IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma (NCT03795610) | Assuntina G. Sacco, MD | 2020-03-06 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure (NCT04278092) | Medical University of Vienna | 2020-02-10 |
| A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (NCT04199104) | Merck Sharp & Dohme LLC | 2020-02-05 |
| Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer (NCT05296135) | Cofactor Genomics, Inc. | 2020-02-05 |